Pharmaceuticals

Global Oral Biologics & Biosimilar Drugs Market Report 2026: Emerging Trends and Growth Scenarios

February 17, 2026February 17, 2026 by Marketing Posting

Uncover key drivers, emerging technologies, and competitive movements shaping the oral biologics & biosimilar drugs market from 2026–2035 with trusted insights from The Business Research Company

What are the forecasted starting (2026) and ending (2030) market sizes for the Oral Biologics & Biosimilar Drugs Market?

The oral biologics & biosimilar drugs market size has expanded significantly in recent years. It is forecast to grow from $8.6 billion in 2025 to $10.41 billion in 2026, exhibiting a compound annual growth rate (CAGR) of 21.0%. Factors contributing to its historical growth include the limited availability of oral biologics, reliance on injectable biologics, the increasing prevalence of autoimmune and inflammatory diseases, growing patient demand for cost-effective therapies, and early approvals of monoclonal antibody drugs.

The oral biologics & biosimilar drugs market size is projected to experience substantial expansion over the coming years. It is anticipated to grow to $17.17 billion by 2030, progressing at a compound annual growth rate (CAGR) of 13.3%. The expected growth during this period stems from the advancement of next-generation oral biologics, the expanding pipeline of biosimilars, increasing uptake of combination therapies, the rise of digital health platforms for patient monitoring, and growing regulatory support for biosimilar approvals. Significant trends in the forecast period involve the increasing adoption of oral biologics and biosimilar drugs, a heightened focus on managing chronic diseases with biologics, the broadening of hospital and retail pharmacy distribution channels, improved patient awareness and acceptance of biosimilars, and the development of targeted therapies for autoimmune and inflammatory conditions.

Access Your Free Sample Report for In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=3792&type=smp

What Drivers Are Supporting Technological Adoption In The Oral Biologics & Biosimilar Drugs Market?

An increasing incidence of chronic illnesses such as arthritis, asthma, and cancer is anticipated to significantly propel the oral biologics and biosimilar market. Factors like extended work hours, reduced physical activity, and unhealthy eating and drinking habits contribute to the widespread occurrence of these chronic conditions, for which biologics are increasingly employed as a treatment. Specifically, biologics stimulate the immune system’s response against cancer cells, aiding in their elimination from the body. For instance, a United Nations article from May 2023 projects that by 2030, the proportion of global deaths due to chronic diseases is expected to increase to 70% of total deaths, with the global burden of chronic disease anticipated to reach about 60%. Consequently, this escalation in chronic disease prevalence is forecasted to boost the demand for biologics and biosimilars, thereby fostering growth in the oral biologics & biosimilar drugs market.

What Segment Types Are Examined In The Oral Biologics & Biosimilar Drugs Market?

The oral biologics & biosimilar drugs market covered in this report is segmented –

1) By Therapy: Lymphocyte Modulators, Interleukin Inhibitors, Tumor Necrosis Factor-Alpha Inhibitors

2) By Disease: Asthma, Crohn’s Disease, Carcinoma, Arthritis, Diabetes, Multiple Myeloma, Enterocolitis, Multiple Sclerosis, Sarcoma, Psoriasis and Others

3) By Molecule Type: Proteins & Peptides, Monoclonal Antibodies, Other Molecule Types

4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

Subsegments:

1) By Lymphocyte Modulators: Fingolimod, Ocrelizumab, Natalizumab

2) By Interleukin Inhibitors: Ustekinumab, Secukinumab, Guselkumab

3) By Tumor Necrosis Factor-Alpha Inhibitors: Adalimumab, Certolizumab Pegol, Golimumab

What Industry Trends Are Transforming The Oral Biologics & Biosimilar Drugs Market?

Leading companies within the oral biologics and biosimilar markets are concentrating on innovative products, such as incretin triagonists, with goals of enhancing patient outcomes, improving drug efficacy, and offering alternatives to therapies requiring injections. Incretin triagonists are medications designed to concurrently activate three hormone receptors—GLP-1, GIP, and glucagon—which play roles in regulating blood sugar, appetite, and metabolism. For example, in October 2024, Rani Therapeutics Holdings Inc., a US-based biotechnology company, published new preclinical pharmacokinetic data affirming the transenteric delivery of a GLP-1 incretin triagonist. Their RaniPill, an oral capsule developed for administering biologics that traditionally require injections, successfully delivered an incretin triagonist aimed at GLP-1, GIP, and glucagon receptors, which are key targets in obesity treatment. The RaniPill showed effectiveness comparable to subcutaneous injections, providing a needle-free option with high bioavailability and adaptable dosing, thus establishing it as a promising solution for future obesity drug candidates.

Who Are The Prominent Global Companies Shaping The Oral Biologics & Biosimilar Drugs Market Landscape?

Major companies operating in the oral biologics & biosimilar drugs market are Novartis International AG, Rani Therapeutics Holdings Inc., Eli Lilly and Company, AstraZeneca plc, Novo Nordisk A/S, Biocon Limited, Oramed Pharmaceuticals Inc., BiosanaPharma, Entera Bio Ltd., Allergan plc, Emisphere Technologies Inc., Enteris BioPharma Inc., Chiasma Inc., Allena Pharmaceuticals Inc., Gelgen Corporation, 3SBio Inc., Innovent Biologics Inc., GlaxoSmithKline PLC, Concord Biotech Limited, Sanofi S.A., F. Hoffmann-La Roche Ltd., Allergan Pharmaceuticals International Limited, Mylan N.V., Pfizer Inc., Sandoz International GmbH, Teva Pharmaceutical Industries Ltd.

Access The Complete Report For Deeper Market Insights:

https://www.thebusinessresearchcompany.com/report/oral-biologics-and-biosimilar-drug-global-market-report

Which Geographic Areas Are Emerging As Strong Markets For The Oral Biologics & Biosimilar Drugs Market?

North America was the largest region in the oral biologics and biosimilar drugs market in 2025. The Middle East is expected to be the fastest growing region in the oral biologics & biosimilar drugs market report during the forecast period. The regions covered in the oral biologics & biosimilar drugs market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request Your Customized Oral Biologics & Biosimilar Drugs Market Research Report for Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=3792&type=smp

Browse Through More Reports Similar to the Global Oral Biologics & Biosimilar Drugs Market 2026, By The Business Research Company

Dental Services Market Report 2026

https://www.thebusinessresearchcompany.com/report/dental-services-global-market-report

Dental Practice Management Market Report 2026

https://www.thebusinessresearchcompany.com/report/dental-practice-management-global-market-report

Dental X Ray Equipment Market Report 2026

https://www.thebusinessresearchcompany.com/report/dental-x-ray-equipment-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795